Progression‐free survival · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower progression‐free survival compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Objective response rate · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher objective response rate (ORR) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ anemia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ thrombocytopenia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
QoL · non‐small cell lung cancer in the elderly population
1 finding from 1 review
Ototoxicity according to NCI CTC v2 criteria with intra‐arterial platinum (combined asymptomatic and symptomatic disease) Exact test method not reported · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in ototoxicity according to NCICTCv2 criteria with intra‐arterial… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Ototoxicity according to Brock criteria with intravenous platinum (combined asymptomatic and symptomatic disease) · children with cancer treated with platinum‐based therapy
Sodium thiosulfate probably leads to lower ototoxicity according to Brock criteria with intravenous platinum… compared with no otoprotective intervention (moderate certainty).
1 finding from 1 review
Overall survival with intravenous platinum (i.e. mortality/number of participants deceased) · children with cancer treated with platinum‐based therapy
Sodium thiosulfate showed no clear difference in overall survival with intravenous platinum (i.e. mortality/number of… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Event‐free survival · children with cancer treated with platinum‐based therapy
Sodium thiosulfate showed no clear difference in event‐free survival with intravenous platinum (i.e. number of… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Tumour response with intravenous platinum (complete and partial remission) · children with cancer treated with platinum‐based therapy
Sodium thiosulfate showed no clear difference in tumour response with intravenous platinum (complete and partial… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Adverse effects other than ototoxicity (≥ grade 3 according to NCICTCAEv3 criteria) with intravenous platinum · children with cancer treated with platinum‐based therapy
1 finding from 1 review
Ototoxicity according to NCI CTC v2 criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Objective and subjective audiometric evaluations were performed, no further information provided · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in ototoxicity according to NCICTCv2 criteria with intravenous platinum… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Ototoxicity according to modified Brock criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Audiograms were performed, but no further information provided · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in ototoxicity according to modified Brock criteria with intravenous… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Tumour response with intra‐arterial platinum (good and partial remission) · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in tumour response with intra‐arterial platinum (good and partial… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Renal toxicity / vomiting/ cardiotoxicity (all grade 3 or higher according to NCI CTCv2 criteria) with intra‐arterial platinum · children with cancer treated with platinum‐based therapy
1 finding from 1 review
Overall survival · people with advanced gastric cancer
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes overall survival compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
Taxane‐platinum‐fluoropyrimidine combinations may leads to higher tumour response compared with taxane‐platinum (without fluoropyrimidine) (low certainty).
1 finding from 1 review
Progression‐free survival · people with advanced gastric cancer
Taxane‐platinum‐fluoropyrimidine combinations probably leads to lower progression‐free survival compared with taxane‐platinum (without fluoropyrimidine) (moderate certainty).
1 finding from 1 review
Treatment‐related death · people with advanced gastric cancer
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment‐related death compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
1 finding from 1 review